Stiolto Respimat
My Prescription
Payment
Select pharmacy
$441.11
$15.00 due at pharmacy
$441.11 - $15.00 = $426.11
$426.11 remaining balance
You will be given your coupon after you complete your purchase with PayPal.
WalmartPowered by$441.11
Print or send this coupon to your phone
WalmartPowered byAbout Stiolto Respimat
Drug Details
Stiolto Respimat is an inhaler prescribed for adults to manage chronic obstructive pulmonary disease (COPD), including conditions such as chronic bronchitis and emphysema. It contains two active medications: tiotropium and olodaterol. Tiotropium is a long-acting muscarinic antagonist (LAMA), while olodaterol is a long-acting beta agonist (LABA). Together, these bronchodilators work by relaxing the muscles around the airways, making it easier to breathe by keeping the airways open. This medication is intended for regular use as a maintenance treatment and should be taken once daily, consisting of two inhalations through the mouth. It is important to note that Stiolto Respimat is not suitable for immediate relief of sudden breathing difficulties. In such cases, a quick-relief inhaler should be used as directed by a healthcare provider. Stiolto Respimat is not approved for treating asthma, and using olodaterol without an inhaled corticosteroid in asthma patients may increase the risk of serious breathing problems. Although side effects are uncommon, they can include upper respiratory tract infections and cough. As with any medication, discuss its use with your doctor or pharmacist to ensure it is safe and effective for your condition.
Price history for Stiolto Respimat
1 Inhaler, 4GM of 2.5-2.5MCG/ACT
Average retail price for Stiolto Respimat
Average SaveHealth price for Stiolto Respimat
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Stiolto Respimat dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 4GM of 2.5-2.5MCG/ACT | 1 Inhaler | $441.11 | $441.11 |
| 4GM of 2.5-2.5MCG/ACT | 2 Inhalers | $877.22 | $438.61 |
| 4GM of 2.5-2.5MCG/ACT | 3 Inhalers | $1,313.34 | $437.78 |
Stiolto Respimat FAQs
Stiolto Respimat is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It helps to improve lung function and reduce symptoms such as shortness of breath. It is not intended for the treatment of acute bronchospasm or asthma.
The choice between Spiriva and STIOLTO depends on the specific needs and medical condition of the patient. Spiriva contains tiotropium, which is a long-acting bronchodilator used for maintenance treatment of chronic obstructive pulmonary disease (COPD). STIOLTO, on the other hand, is a combination of tiotropium and olodaterol, providing both a long-acting muscarinic antagonist and a long-acting beta-agonist, which may offer additional benefits for some patients with COPD.The decision on which medication is better should be made by a healthcare provider, considering the patient's overall health, severity of symptoms, and response to previous treatments. It is important for patients to discuss their options with their healthcare provider to determine the most appropriate treatment plan.
Stiolto does not contain steroids. It is a combination of two bronchodilators: tiotropium, which is a long-acting muscarinic antagonist (LAMA), and olodaterol, a long-acting beta-agonist (LABA).
The most commonly seen adverse reaction when using STIOLTO is nasopharyngitis, which is an inflammation of the nasal passages and throat.
An inhaler that is comparable to Stiolto Respimat is Anoro Ellipta. Both are combination inhalers used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and contain a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA). However, it is important for patients to consult with their healthcare provider to determine the most appropriate treatment for their specific condition.